ZimVie agreed to be acquired by an affiliate of the healthcare investment firm Archimed for $19 a share in cash, valuing the dental implant company at about $730 million.
The price represents a 99% premium to ZimVie’s 90‑day volume‑weighted average price of $9.57. ZimVie’s board unanimously approved the transaction, which is expected to close by year‑end 2025, pending shareholder and regulatory approvals.
Related: RadNet acquires See-Mode to bolster AI ultrasound screening for thyroid cancer
“This transaction marks a new chapter for ZimVie and underscores the value our team has built over the past several years,” ZimVie CEO Vafa Jamali said. “Partnering with Archimed will create value for our shareholders while providing the strategic and financial backing to expand our innovative dental technology to more patients globally.”
ZimVie may solicit superior offers for 40 days through Aug. 29, 2025. If the deal closes, ZimVie will become a privately held company and its shares will be delisted from Nasdaq.
“We’re excited to partner with ZimVie and its talented team,” said Archimed Managing Partner André-Michel Ballester. “The company has strong fundamentals and compelling growth potential, and we look forward to supporting its next chapter.”
ZimVie began operating independently in March 2022, when Zimmer Biomet completed the spinoff of its spine and dental businesses into the newly named company.
Management moved to focus on dentistry the following year, agreeing in December 2023 to sell the spine unit to H.I.G. Capital for $375 million; the sale closed in April 2024.
By June 2024, Bloomberg reported that ZimVie was exploring a possible sale or other strategic alternatives after receiving takeover interest, a process that led to the agreement announced today.
